Vanguard Capital Management
VKTX icon

Vanguard Capital Management’s Viking Therapeutics VKTX Stock Holding History

Vanguard Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$197M Buy
5,053,663
+41,161
+0.8% +$1.33M ﹤0.01% 1144
2026
Q1 		$163M Buy
+5,012,502
New +$161M ﹤0.01% 1197

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management's VKTX Position: Q2 2026 in Review

Vanguard Capital Management increased its Viking Therapeutics (VKTX) stake by 0.82% in Q2 2026, buying an estimated $1.33M and bringing the position to 5,053,663 shares worth $197M. The position accounts for ﹤0.01% of the portfolio, ranked #1144.

Vanguard Capital Management first reported a position in VKTX in Q1 2026 and has held it in 2 quarters since. 424 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Vanguard Capital Management held 5,053,663 shares of Viking Therapeutics worth $197M as of Q2 2026.
  • Vanguard Capital Management bought 41,161 Viking Therapeutics shares in Q2 2026, an estimated $1.33M.
  • Viking Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1144 holding.
  • Vanguard Capital Management first reported a position in Viking Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 424 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.